Artelo Biosciences (NASDAQ:ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial (IST) is backed by Glaucoma UK and the HSC R&D Division, with first patient enrollment anticipated in Q2 2026. The announcement represents a significant pipeline diversification for the San Diego-based clinical-stage biopharmaceutical company — and one that does not require dilutive equity financing from shareholders.

A $16.3 Billion Market Growing Faster Than Its Treatment Options

The global glaucoma market was valued at USD 9.46 billion in 2025 and is projected to reach USD 16.31 billion by 2033, growing at a compound annual growth rate of 7.05%. Approximately 145.9 million people were affected by glaucoma in 2021, a figure expected to climb to 166 million by 2026. In the United States alone, 4.2 million adults had glaucoma in 2022, with 1.5 million experiencing vision impairment. U.S. cases are projected to reach 6.3 million by 2050.

The patient population is expanding faster than treatment innovation — a gap that defines the opportunity Artelo is now pursuing.

Why ART27.13 Is Differentiated

Despite a broad pharmacological toolkit available to clinicians, a significant proportion of glaucoma patients continue to experience disease progression. Standard-of-care treatments focus primarily on lowering intraocular pressure (IOP), leaving the underlying neuroprotective needs of patients unaddressed.

ART27.13 is a peripherally selective synthetic cannabinoid receptor agonist. Preclinical data indicates the compound can modulate IOP through aqueous humor dynamics and ocular blood outflow — without the central nervous system side effects that have historically prevented cannabinoid-based therapies from gaining clinical traction in ophthalmology. ART27.13 targets CB2 receptors specifically, which mediate anti-inflammatory, anti-apoptotic, and neuroprotective properties, offering a therapeutic mechanism that goes beyond simple pressure reduction.

The science supporting cannabinoid-based glaucoma treatment has existed since the 1970s. Peripheral selectivity and the CB2-targeting design are what distinguish theoretical benefit from clinical viability.